$2.35 Billion by 2030: Why In Situ Hybridization Is Revolutionizing Molecular Diagnostics
What's driving the shift to spatially resolved molecular analysis?
The global in situ hybridization market, valued at USD 1.64 billion in 2025, is projected to reach USD 2.35 billion by 2030, growing at a CAGR of 7.4%. This growth is driven by the expanding role of ISH in precision medicine, laboratory-developed tests (LDTs), and spatial transcriptomics. Technological innovations—including multiplex ISH, high-sensitivity probes, and automation—are enabling more accurate, efficient, and spatially resolved gene expression analysis in both clinical and research settings. From oncology to neuroscience, ISH is paving the way for advanced diagnostics and next-generation therapeutic strategies.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=212028829
Why is ISH becoming a molecular game-changer?
In Situ Hybridization methods such as FISH and RNA-ISH are increasingly used to detect patient-specific genetic markers at the single-cell level. These techniques offer greater specificity and spatial resolution than conventional assays. For instance, Molecular Instruments' HCR Pro RNA-ISH LDT (Feb 2025) now enables differentiation between psoriasis and atopic dermatitis based on biopsy-derived immunologic markers—transforming diagnostics for millions with chronic skin conditions.
Key players like Precision for Medicine, Scantox, and Plus Therapeutics are leveraging ISH to support oncology, gene therapy, and neurodegenerative disease research, further embedding these tools in drug development pipelines and personalized treatment planning.
What challenges does ISH solve?
ISH technologies address a number of persistent issues in molecular and histopathological diagnostics:
Enables precise spatial mapping of gene expression across tissues.Improves accuracy in difficult diagnoses where IHC or sequencing alone falls shortSupports multi-target detection for robust biomarker discovery and validation.Advances translational research through integration of transcriptomic and proteomic analyses.
For example, Roche's FDA-cleared VENTANA Kappa and Lambda Dual ISH mRNA assay (Jan 2025) enhances lymphoma subtype detection, representing a breakthrough in ISH-based molecular diagnostics.
Where is adoption accelerating the fastest?
While North America leads with the largest market share due to established infrastructure and funding, rapid growth is forecasted in the Asia Pacific, driven by rising cancer incidence, government funding, and diagnostic modernization.
Key momentum drivers include:
China, India, and Japan investing heavily in molecular pathology infrastructure.Regional labs expanding ISH capabilities for cancer and infectious disease diagnostics.Accelerated academic and CRO adoption of automated, scalable ISH platforms.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=212028829
Who are the key leaders—and how are they gaining ground?
The ISH market is consolidated, with 5 major players holding 60–65% of global market share:
F. Hoffmann-La Roche Ltd (Switzerland): Leading in automated ISH diagnostics, including BenchMark ULTRA PLUS and FDA-cleared lymphoma probes.
Danaher (US): Through Leica Biosystems, focuses on integrated automation and spatial biology tools.Abbott (US): Dominant in ISH probes for oncology and cytogenetics under the VYSIS brand.Bio-Techne (US): RNAscope portfolio expansion to 70,000+ probes position it as a spatial transcriptomics leader.Thermo Fisher Scientific (US): Offers a comprehensive suite of ISH instruments and consumables.
Recent innovations include:
Leica + Bio-Techne (Apr 2025): Automated RNAscope Multiomic LS for spatial multiomics.Leica + Molecular Instruments (Jan 2025): Launched HCR Pro RNA-ISH for high-sensitivity multiplexing.Roche (Jan 2025): FDA-cleared B-cell ISH diagnostic.Vitro + Biocare (Mar 2025): NeoPATH Pro ISH system distributed in the US.
What's the biggest challenge—and how do we overcome it?
Despite promising advances, high costs and technical complexity remain barriers:
Capital investment: ISH instruments like Ventana Benchmark Ultra cost ~$100,000.Consumables: Multiplex probe kits and imaging services are costly, with per-slide fees reaching $113 or more.Labor-intensive protocols: Require skilled personnel and careful optimization.Imaging costs: Advanced scanners such as Vectra can cost $200/hour to operate.
Solutions must focus on:
User-friendly automation platforms with streamlined protocols.Reagent optimization to reduce cost per assay.Training initiatives to expand technical capacity.Scalable, modular platforms for research and clinical users alike.
What should diagnostics leaders be asking now?
Not 'Is ISH useful?'—but rather:
How can ISH improve our ability to detect spatial gene expression at single-cell resolution?Which multiplexing and automation technologies can scale with our diagnostics needs?Are our assays ready for regulatory validation and clinical deployment?How can we integrate transcriptomics and proteomics within one platform?
Final Thought: In Spatial Precision, There Is Power. In Multiplexing, There Is Clarity.
As genomics shifts toward spatial, multiplexed, and clinically actionable diagnostics, in situ hybridization is evolving from a research tool into a cornerstone of precision healthcare. It's not just about detection anymore—it's about localization, integration, and transformation of diagnostics.
In the future of molecular medicine, personalization begins with precision—and ISH is leading the charge.
Key Market Players:
F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), Abbott (US), Bio-Techne (US), Thermo Fisher Scientific (US), Bioview (Israel), Biocare Medical (US), Agilent Technologies (US), QIAGEN (Germany), CytoTest Inc. (US), Genemed Biotechnologies (US), ZytoVision GmbH (Germany), Abnova (Taiwan)
For more information, Inquire Now!
Related Reports:
Companion Diagnostics Market
Immunohistochemistry Market
Tissue Diagnostics Market
Immuno Oncology Assays Market
Cancer Diagnostics Market
Get access to the latest updates on Top Companies in In Situ Hybridization and In Situ Hybridization Market Size
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@marketsandmarkets.comVisit Our Website: https://www.marketsandmarkets.com/
Logo; https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/2-35-billion-by-2030-why-in-situ-hybridization-is-revolutionizing-molecular-diagnostics–marketsandmarkets-302499852.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
an hour ago
- Malaysian Reserve
CENTERSPACE ANNOUNCES SECOND QUARTER 2025 EARNINGS RELEASE DATE
MINNEAPOLIS, July 8, 2025 /PRNewswire/ — Centerspace (NYSE: CSR) will release its operating results for the quarter ended June 30, 2025, after the market closes on Monday, August 4, 2025. Management will host a conference call to discuss those results on Tuesday, August 5, 2025, at 10:00 a.m. Eastern Time. Interested parties may access the conference call via the following: Live Conference Call Details: Live webcast: Operator Assisted Dial-In:United States (Local): +1 404 975 4839United States (Toll-Free): +1 833 470 1428Canada: +1 226 828 7575Canada (Toll-Free): +1 833 950 0062Access Code: 547256 Replay Details: Replay Expiration Date: Tuesday, August 12, 2025 11:59 PM EDT Replay Dial-In:United States (Local): +1 929 458 6194United States (Toll-Free): +1 866 813 9403Access Code: 134183 About Centerspace Centerspace is an owner and operator of apartment communities committed to providing great homes by focusing on integrity and serving others. Founded in 1970, the company currently owns 72 apartment communities consisting of 13,353 homes located in Colorado, Minnesota, Montana, Nebraska, North Dakota, South Dakota, and Utah. Centerspace was named a top workplace for the sixth consecutive year in 2025 by the Minneapolis Star Tribune. For more information, please visit If you would like more information about this topic, please contact Josh Klaetsch, Investor Relations, at (952) 401-6600 or IR@ Contact Information Josh Klaetsch, Investor Relations Phone : (952) 401-6600 E-mail : IR@
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Collective Project Launches Bold New Portfolio of Hemp-Derived THC Beverages in the U.S.
Top selling Canadian cannabis beverage brand known for creative collaborations and flavor-forward beverages now shipping direct-to-consumer across the country NEW YORK, July 8, 2025 /PRNewswire/ — Collective Project, the Canadian cannabis beverage brand known for its bold flavor pairings, real fruit juices, and creative can design collaborations with emerging artists, has officially launched in the U.S. with direct-to-consumer shipping in 25 states.* This major milestone follows Collective Project's acquisition earlier this year by Organigram Global, Canada's #1 cannabis company by market share. After a soft launch of its sparkling juice lineup in select states in Fall 2024, Collective Project built early excitement for its flavorful, fruit-forward beverages. The brand now expands to consumers across the country with full-scale e-commerce and the debut of its new sparkling lemonades – all crafted with real fruit juice, high-quality ingredients, and hemp-derived THC. At Collective Project, every can is a canvas. Every beverage is a collaboration between the brand's flavor creators and visual artists from around the world, transforming every product into a functional piece of art. Through this global creative platform, Collective Project brings together expressive design, great taste, and a modern way to enjoy cannabis. 'Collective Project is rooted in flavor and creativity,' said Megan McCrae, SVP, Corporate Strategy & International Growth, Organigram Global. 'We're proud to partner with artists from around the world to create cans that reflect the vibrant community behind our brand. And as the hemp-derived Delta-9 space grows, we see a real opportunity to offer consumers a modern, social alternative to alcohol – one that brings together great taste, thoughtful ingredients, and artistic expression.' Sparkling JuicesThe sparkling juice lineup offers rich, effervescent flavors made with true-to-fruit blends for an unmatched full-body experience. Currently available in 4-packs (12oz cans): Blood Orange, Yuzu & Vanilla (available in 5mg and 10mg THC) Mango, Pineapple & Coconut (available in 5mg and 10mg THC) Raspberry Vanilla (available in 10mg THC) New: Sparkling LemonadesThe sparkling lemonades offer a zesty, low-calorie, and low-sugar option that adds a bubbly twist to every celebration. Available in 4-packs (12oz cans): Classic Lemonade (available in 5mg THC) Raspberry Lemonade (available in 5mg THC) Cherry Limeade (available in 5mg THC) All beverages are made with high quality hemp-derived THC and are tested by independent third parties for consistency, quality, and compliance. With a variety of THC levels, there's a dose for every kind of cannabis experience and lifestyle. Collective Project products are available for purchase by consumers 21+. Collective Project is available online at for shipping directly to many states and at select retailers including Total Wine (IN, MN, NC, SC) and Top Ten (MN). The brand will also introduce Fetch, a new line of bold hemp-derived THC sodas, later this summer, with full details to be announced closer to launch. To place an order, explore the full lineup, or meet the artists behind the cans, visit and follow @drinkcollectiveproject on Instagram. *Collective Project is now shipping to Arkansas, Delaware, Florida, Georgia, Illinois, Indiana, Kansas, Maine, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Wisconsin, and Wyoming. ABOUT COLLECTIVE PROJECTCollective Project is a Canadian cannabis and U.S. hemp beverage brand. Collective Project believes that a creative world is a better world and we're on a mission to bring inspiration, collaboration, and creativity into everyday life. Our hemp-derived THC beverages are made with real fruit juice, clean ingredients, and balanced dosing, offering a bold, flavorful way to enjoy hemp-derived products. More than a drink, each can is a collaboration between flavor creators and visual artists, turning everyday moments into something expressive, social, and a little more inspired. ABOUT ORGANIGRAMOrganigram Global Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. Through its acquisition of Collective Project Limited, Organigram Global participates in the U.S. and Canadian cannabinoid beverage markets through the sale of the Collective Project and Fetch THC beverage brands. Media Contact: collectiveproject@
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Macrovey to Host Mobile Robot Bootcamp July 14-15 in Alpharetta
ALPHARETTA, Ga., July 7, 2025 /PRNewswire/ — Macrovey is proud to announce its upcoming Mobile Robot Bootcamp, taking place July 14–15 at the Macrovey Technology Center in Alpharetta. The immersive two-day event, hosted in partnership with the Alliance Academy for Innovation, is designed to give students practical experience in robotics, automation, and artificial intelligence. Through guided sessions, students will explore topics including motion control, sensor-based navigation, object tracking, and autonomous behaviors. Each session pairs core concepts with hands-on implementation, preparing students to solve real-world automation challenges. Bootcamp highlights include: Mecanum drive control and PID tuning Color, QR code, and face tracking Line following, obstacle avoidance, and gesture recognition Autonomous driving simulations and final system integration The event is part of Macrovey's broader initiative to expand access to advanced technical training through collaboration with local schools and industry partners. Event Details:Dates: July 14–15, 2025Time: 9:00 AM – 5:00 PM each dayLocation: Macrovey Technology Center, Alpharetta, GA Educators, media, and community leaders interested in attending or learning more are encouraged to contact Macrovey directly at
